Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna was a pioneer in mRNA. This company hopes to be a winner with eRNA.

Could This Biotech Start-Up Be the Next Moderna?

AstraZeneca

Japan has approved the COVID-19 vaccines produced by Moderna Inc (NASDAQ:MRNA) and by AstraZeneca PLC (LON:AZN) in conjunction Oxford University, for people aged over 18. Japan has so far only vaccinated around 2% of its population of 125mln, using the Pfizer jab.

AstraZeneca and Moderna receive approval for COVID-19 vaccines in Japan

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Japan's Ministry of Health, Labour and Welfare (MHLW) approves Moderna's COVID-19 vaccine.

Japan's Ministry of Health, Labour and Welfare (MHLW) Approves Moderna's COVID-19 Vaccine

Two news items on the opposite side of the world pushed the shares up on the day.

Why Moderna Shot 5%-Plus Higher on Thursday

Moderna Inc (NASDAQ:MRNA) shares are trading higher by 4.7% at $165.44 Thursday afternoon after a Japan health panel recommended approval of the company's COVID-19 vaccine. Moderna is engaged in creating transformative medicines based on messenger RNA, or mRNA.

What's Going On With Moderna Stock Today?

Moderna's Covid-19 success has given it the scale and funds to be a big player in vaccines, making MRNA stock a strong long-term buy. The post Moderna Holds the Key to the Future of mRNA Vaccines appeared first on InvestorPlace.

Moderna Holds the Key to the Future of mRNA Vaccines

Many Americans could start receiving booster shots as soon as this fall. Moderna CEO Stéphane Bancel said in an email on Wednesday that people who are at highest risk from COVID-19, like healthcare workers and the elderly, could require a third shot in September, Axios' Caitlin Owens reports.

Moderna CEO says some Americans could start getting a COVID-19 booster shot as soon as September (MRNA)

Moderna is poised for a solid 2021 as it ramps up sales of its much sought-after Covid-19 vaccine. The company is on track to deliver between 800 million to 1 billion doses of the shot this year and based on its advance purchase agreements, sales for the year could top $19 billion, up from less.

What's 2022 Looking Like For Moderna Stock?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to host fourth annual Science Day on May 27, 2021.

Moderna to Host Fourth Annual Science Day on May 27, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to establish an international business services hub in Warsaw, Poland.

Moderna to Establish an International Business Services Hub in Warsaw, Poland

Seagen

Vertex Pharmaceuticals

Their revenue prospects are the ticket to future share price performance.

3 Biotech Stocks You'll Be Glad You Bought at These Prices

BioNTech SE

Johnson & Johnson

Pfizer

Vaccine makers, including Pfizer, Johnson & Johnson, AstraZeneca, and BioNTech, are set to make billions for many years to come.

Vaccine Makers Will Make Billions For Years To Come: Which One To Buy Now

The biotech came out of nowhere to vault near the top of this survey ranking.

Here's 1 Surprising Ranking Where Moderna Handily Beats Pfizer

Those plans come after the White House said it would send 60 million doses of AstraZeneca's Covid vaccine to countries in need

Biden to say U.S. will send 20 million Pfizer, Moderna or J&J vaccine doses abroad by end of June

Intel

Netflix

Wells Fargo

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. This time, our artificial intelligence systems have identified IBM and Netflix among other trending stocks.

Artificial Intelligence Identifies IBM And Netflix Among Trending Stocks This Week

A country rapidly going maskless could benefit the biotech handsomely.

Why Moderna Was a Big Winner on Friday

A hint: They all have to do with the future.

3 Things About Moderna That The Smartest Investors Know

Moderna Inc (NASDAQ: MRNA) has announced a new agreement to supply 25 million doses of its COVID-19 vaccine to Australia. The deal includes 10 million doses of the company's mRNA-1273 vaccine delivered this year and 15 million doses of its variant booster vaccine candidate to be delivered in 2022.

Moderna Inks 25M COVID-19 Shots Supply Pact With Australia

Moderna Inc. announced Wednesday a new agreement to supply 25 million doses of its COVID-19 vaccine to Australia. The agreement includes 10 million doses of the biotechnology company's mRNA-1273 vaccine to be delivered this year and 15 million doses of its variant booster vaccine candidate to be delivered in 2022.

Moderna's new supply deal with Australia is for 25 million COVID-19 vaccine doses

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces new Supply agreement with Australia for 25 million doses of its COVID-19 vaccine.

Moderna Announces New Supply Agreement with Australia for 25 Million Doses of its COVID-19 Vaccine

Let's look to the long term for our answer.

Does Pfizer's Latest News Snatch a Big Market Opportunity Away From Moderna?

Here Are the 3 Most Important Numbers in Moderna's Earnings Report

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. And our deep-learning algorithms have found this week's trending stocks, including Netflix and Moderna.

Netflix And Moderna Among This Week's Trending Stocks

Some folks are worried about protections for vaccine-related intellectual property, but MRNA stock investors have plenty of reasons to relax. The post Why Moderna Shareholders Should Savor First Quarterly Profit Results appeared first on InvestorPlace.

Why Moderna Shareholders Should Savor First Quarterly Profit Results

Novavax

The Covid-19 treatment response process includes a number of different major players, including Pfizer Inc (NYSE: PFE), BioNTech SE – ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA), AstraZeneca plc (NASDAQ: AZN), Novavax Inc (NASDAQ: NVAX), Halberd Corp (OTC US: HALB), and Johnson & Johnson (NYSE: JNJ). The pandemic is under control.

News for Moderna Stock (MRNA)